Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Loxo Edges Closer To Commercial Market With Larotrectinib, But Diagnostic Challenge Persists

29 May 2018

• By Jessica Merrill

Digital illustration of Cancer cell in colour background

Related Content

Biomarker-Led Claim Is Small Step For Merck's Keytruda, Giant Leap For Cancer Indications

23 May 2017

Loxo’s Tissue-Agnostic Approach Brings $400m Upfront From Bayer

14 Nov 2017

Other ASCO 2018 Highlights – It’s Not All IO

18 May 2018

Loxo Sees Larotrectinib As Model Form Of Oncology Drug Development

05 Jun 2017

Loxo's Larotrectinib Requires Paradigm-Change In Clinical Practice

05 Jun 2017

Medicare Finalizes NGS Test Coverage For Advanced Cancers, Drops Evidence-Collection Provision

16 Mar 2018

Related Companies

Loxo Oncology at Lilly

Merck & Co., Inc.

Illumina, Inc.

Bayer AG

Additional Topics

Drug Review Launches Commercial Cancer BioPharmaceutical

More from Anticancer

More from Therapy Areas

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.